Chul S. Ha
Baylor College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chul S. Ha.
Leukemia & Lymphoma | 1997
Andreas H. Sarris; Vali Papadimitrakopoulou; Meletios A. Dimopoulos; Terry L. Smith; William C. Pugh; Chul S. Ha; Peter McLaughlin; David L. Callender; James D. Cox; Fernando Cabanillas
Since the reported survival and failure-free survival (FFS) of adults with primary parotid non-Hodgkins lymphoma (NHL) is variable, we reviewed our experience of untreated adults with primary parotid NHL. Patients were eligible if they presented to the University of Texas M. D. Anderson Cancer Center Cancer between 1980 and 1995 with parotid enlargement and if the diagnosis of lymphoma was verified according the Working Formulation. Medical records were reviewed to determine Ann Arbor Stage (AAS), the International Prognostic Index (IPI) score, response to therapy, relapse, FFS, and survival. We identified 39 untreated adults with primary parotid NHL representing 1% of all lymphomas and 8.6% of all untreated parotid neoplasms. Three patients were excluded because of suboptimal therapy, leaving 36 patients eligible for outcome analysis. Of the 18 patients with low-grade NHL, two were treated with radiotherapy, eight with chemotherapy and radiotherapy, seven with chemotherapy only, and one with antibiotics. The complete remission (CR) rate was 94%, and with a median follow-up of 36 months for surviving patients the survival and failure-free survival (FFS) at 5 years were 94% and 78%, respectively. The 5-year FFS were not statistically different between patients with early (I or II) or advanced (III or IV) AAS (83% and 74%, respectively; p > 0.05) and favorable (0 or 1) or unfavorable (> 1) IPI scores (73% and 100%, respectively; p > 0.05). All 18 patients with intermediate-grade NHL were treated with doxorubicin-based chemotherapy which was followed by radiotherapy in six. The CR rate was 89%, and with a median follow-up of 51 months for surviving patients the survival and FFS at 10 years were 80% and 72%, respectively. In this group 10-year FFS was better in early than in advanced AAS (100% vs 0%, respectively; p = 0.01) and in favorable (0 or 1) than in unfavorable (> 1) IPI scores (86% vs 20%, respectively; p < 0.01). We conclude the the FFS of patients with low-grade NHL is 78% and not affected by AAS or IPI score. The FFS of patients with intermediate-grade NHL appears comparable with that of NHLs of other primary sites, being 86% for those with IPI < or = 1 and 20% for those with IPI 1. Patients with IPI > 1 should be entered on investigational protocols aiming to increase FFS.
Cell Biology International Reports | 1983
Fred R. Harmon; William H. Spohn; Naochika Domae; Chul S. Ha; Harris Busch
Small ring-shaped miniparticles, found in the nucleus nucleolus and cytoplasm of a variety of normal and malignant cells, have been purified by a procedure involving differential and gradient centrifugation, hydroxylapatite chromatography and preparative electrophoresis. They are multisubunit proteins comprised of at least six polypeptide chains of Mr 20,000-30,000 Daltons (by one-D SDS-PAGE which present a series of 20-30 spots on two-D IEF/SDS gels. They can be reversibly dissociated in EDTA containing buffers. They are not membrane associated and contain no carbohydrate. They have an S20,W of 21S on sucrose gradients. They are immunologically similar in several human cell lines.
Archive | 2011
Valerie Klairisa Reed; Jatin J. Shah; L. Jeffery Medeiros; Chul S. Ha; Ali Mazloom; Donna M. Weber; I. Arzu; Robert Z. Orlowski; Sheeba K. Thomas; Ferial Shihadeh; Raymond Alexanian; Bouthaina S. Dabaja
Radiation Oncology (NINTH EDITION) | 2010
Bouthaina S. Dabaja; Chul S. Ha; James D. Cox
Archive | 2003
John F. Seymour; Barbara Pro; Lillian M. Fuller; John T. Manning; Fredrick B. Hagemeister; Jorge Romaguera; Maria Alma Rodriguez; Chul S. Ha; Terry L. Smith; Ana Ayala; Mark A. Hess; James D. Cox; Fernando Cabanillas; Peter McLaughlin
International Symposium on Hodgkin's Lymphoma | 2002
Richard B. Wilder; Pamela J. Schlembach; Dan Jones; Gregory M. Chronowski; Chul S. Ha; Anas Younes; Fredrick B. Hagemeister; Ibrahim Barista; Fernando Cabanillas; James D. Cox
International Symposium on Hodgkin Lymphoma | 2002
Gregory M. Chronowski; Richard B. Wilder; Susan L. Tucker; Chul S. Ha; Andreas H. Sarris; Fredrick B. Hagemeister; Ibrahim Barista; Mark A. Hess; Fernando Cabanillas; James D. Cox
Archive | 2001
Andreas H. Sarris; Ira Braunschweig; L. Jeffrey Medeiros; Madeleine Duvic; Chul S. Ha; M. Alma Rodriguez; Frederick B. Hagemeister; Peter McLaughlin; Jorge Romaguera; James D. Cox; Fernando Cabanillas
Annual Meeting of the American Society for Therapeutic Radiology and Oncology | 2001
Ramesh Gopal; Chul S. Ha; Susan L. Tucker; Issa F. Khouri; Sergio Giralt; James Gajewski; Borje S. Andersson; James D. Cox; Richard E. Champlin
Archive | 2000
Hagop M. Kantarjian; Terry L. Smith; Jorge Cortes; Francis J. Giles; Miloslav Beran; Sherry Pierce; Yang Huh; Michael Andreeff; Charles Koller; Chul S. Ha; Michael J. Keating; Sharon Murphy; Emil J. Freireich